Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection - PRNewswire
Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection PRNewswire
SAN DIEGO, May 28, 2019 /PRNewswire/ -- Ansun Biopharma, Inc., today announced that the first patient has been enrolled in its Phase 3 clinical trial ...
Comments
Post a Comment